Works matching IS 2160763X AND DT 2015 AND VI 4 AND IP 2
Results: 13
Effects of ketoconazole on the pharmacokinetics of lenvatinib (E7080) in healthy participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 155, doi. 10.1002/cpdd.140
- By:
- Publication type:
- Article
Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 137, doi. 10.1002/cpdd.145
- By:
- Publication type:
- Article
A soft benzodiazepine.
- Published in:
- 2015
- By:
- Publication type:
- Editorial
The effects of the nonselective benzodiazepine lorazepam and the α<sub>2</sub>/α<sub>3</sub> subunit-selective GABA<sub>A</sub> receptor modulators AZD7325 and AZD6280 on plasma prolactin levels.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 149, doi. 10.1002/cpdd.134
- By:
- Publication type:
- Article
Pharmacokinetics of single and repeat doses of icatibant.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 105, doi. 10.1002/cpdd.138
- By:
- Publication type:
- Article
Effects of icosapent ethyl (Eicosapentaenoic acid ethyl ester) on pharmacokinetic parameters of rosiglitazone in healthy subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 143, doi. 10.1002/cpdd.150
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- 2015
- Publication type:
- Other
Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 83, doi. 10.1002/cpdd.171
- By:
- Publication type:
- Article
Pharmacokinetic drug-drug interaction study of ranolazine and metformin in subjects with type 2 diabetes mellitus.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 121, doi. 10.1002/cpdd.174
- By:
- Publication type:
- Article
An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 112, doi. 10.1002/cpdd.175
- By:
- Publication type:
- Article
PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 89, doi. 10.1002/cpdd.176
- By:
- Publication type:
- Article
A comparative pharmacokinetic and pharmacodynamic study of FSK0808 versus reference filgrastim after repeated subcutaneous administration in healthy Japanese men.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 99, doi. 10.1002/cpdd.178
- By:
- Publication type:
- Article
Intravenous pharmacokinetics, local tolerability, and hemolysis of an SBE7-β-cyclodextrin formulation of the neurokinin-1 receptor antagonist vestipitant.
- Published in:
- Clinical Pharmacology in Drug Development, 2015, v. 4, n. 2, p. 130, doi. 10.1002/cpdd.128
- By:
- Publication type:
- Article